MT 3995

Drug Profile

MT 3995

Alternative Names: MT-3995

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Class Antihyperglycaemics; Antihypertensives
  • Mechanism of Action Aldosterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies; Non-alcoholic steatohepatitis
  • Discontinued Hypertension

Most Recent Events

  • 01 Jan 2017 Mitsubishi Tanabe Pharma Corporation completes a phase II trial for Diabetic nephropathies in Japan (NCT02517320)
  • 01 Dec 2016 Mitsubishi Tanabe completes a phase I trial in Diabetic nephropathies (In volunteers) in United Kingdom (PO) (NCT02900235)
  • 02 Oct 2016 Phase-II clinical trials in Non-alcoholic steatohepatitis in Japan (PO) before October 2016 (NCT02923154)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top